BluGlass Secures $6.6M From Options Exercise With Strong Shareholder Support
BluGlass secures $6.6 million from options exercise and shortfall placement
BluGlass Limited has received $6.56 million in total proceeds connected to its $0.26 Options that expired on 31 May 2026. The funding comprises $5.06 million from option holders exercising their options and $1.5 million via a Shortfall Agreement with Amery Partners. This follows the company’s upsized $8 million institutional placement completed in April 2026, bolstering the GaN laser developer’s recent recapitalisation.
The high option participation rate signals confidence in BluGlass’s commercial trajectory among current investors. Option holders choosing to exercise rather than letting their rights lapse indicates belief in the company’s ability to deliver on its contract pipeline and maintain technical leadership in the visible laser market.
When big ASX news breaks, our subscribers know first
Breakdown of the capital raise
The $6.56 million in total option proceeds breaks down into two distinct components. Under the Shortfall Agreement, BluGlass issued 5,769,230 fully paid ordinary shares at $0.26 per share to Amery Partners. Each Shortfall Share includes one unquoted free-attaching option exercisable at $0.38 and expiring on 31 May 2028 (termed “Piggyback Options”). Shareholder approval will be sought at the 2026 Annual General Meeting for the issue of these Piggyback Options under the Shortfall Agreement.
| Funding Component | Amount | Terms |
|---|---|---|
| Option holder exercises | $5.06 million | $0.26 Options |
| Shortfall Agreement (Amery Partners) | $1.5 million | 5,769,230 shares at $0.26 |
| Total Options proceeds | $6.56 million |
The Piggyback Option structure creates a potential future capital event at the higher $0.38 strike price, providing BluGlass with visibility on possible additional funding through to 31 May 2028.
What are options in a capital raise?
Listed options give holders the right, but not the obligation, to purchase shares at a predetermined price (the strike price) before a specified expiry date. In BluGlass’s case, the original $0.26 Options allowed holders to buy shares at $0.26 before 31 May 2026. Holders who believed the company’s share price would exceed $0.26 had an incentive to exercise their options, converting them into ordinary shares.
A shortfall agreement is an arrangement where a third party agrees to subscribe for any options not exercised by existing holders. This mechanism ensures the company secures a minimum level of funding regardless of option holder participation rates. Amery Partners fulfilled this role by subscribing for $1.5 million in Shortfall Shares.
The high participation rate on the $0.26 Options suggests existing shareholders believe the current share price trajectory and the company’s commercial prospects justified exercising rather than letting their options lapse. The attached Piggyback Options, exercisable at the higher $0.38 strike price, create a staged funding structure that aligns future capital availability with anticipated business growth.
How BluGlass will deploy the funds
Proceeds from the options exercise and Shortfall Agreement will be directed toward three primary areas:
- Delivery of new and existing GaN laser contracts
- Working capital requirements
- Investment in manufacturing facilities, team expansion, and next-generation capabilities
Executive Chair Omer Granit emphasised that recapitalising the business has been a Board priority, with the proceeds positioning BluGlass to convert pipeline opportunities while maintaining its technical edge.
Omer Granit, Executive Chair
“We appreciate the continued support from our loyal shareholders with the high Option participation rate reflecting BluGlass’ significant commercial and technical progress over the past six months. Recapitalising the business has been a priority for the Board with these proceeds enabling increased investment in our manufacturing facilities, team, and next-generation capabilities, ensuring we are well-placed to deliver existing contracts and convert new opportunities in the pipeline. At the same time, our recent world-record single-mode laser performance has reinforced the cutting-edge nature of our technology, supporting discussions with potential customers from across our target verticals.”
The funding structure allows BluGlass to scale its operations in line with customer demand whilst continuing to advance its proprietary remote plasma chemical vapour deposition (RPCVD) manufacturing technology.
Recent momentum supporting the raise
BluGlass achieved world-record single-mode laser performance in recent months, a technical milestone that has supported customer discussions across its target verticals: industrial, defence, bio-medical, and scientific applications. As one of just a handful of end-to-end GaN laser manufacturers globally, the company occupies a niche position in the photonics industry.
The world-record single-mode laser performance achieved in May 2026 produced a verified 1.9W peak output from a single monolithic GaN chip at 450nm, a 52% improvement over BluGlass’s own prior benchmark and independently confirmed by the University of California, Santa Barbara.
The capital raise enables BluGlass to convert pipeline opportunities whilst maintaining its technical leadership position. The combination of commercial contract delivery and cutting-edge research and development achievements creates a dual value proposition for investors: near-term revenue generation from existing contracts alongside longer-term growth potential from next-generation laser capabilities.
The high option participation rate reflects shareholder recognition of the company’s significant commercial and technical progress over the past six months. BluGlass operates facilities in both Australia and the United States, offering custom laser diode development and manufacturing from small-batch prototypes through to medium and high-volume off-the-shelf products.
The next major ASX story will hit our subscribers first
Capital position and upcoming catalysts
BluGlass has substantially strengthened its balance sheet through two recent funding events: the April 2026 institutional placement of $8 million and the $6.56 million in option proceeds secured in connection with the 31 May 2026 expiry.
The April 2026 institutional placement raised $8 million across two tranches at $0.24 per share, with BluGlass citing a US$100 million project pipeline and a 97% revenue CAGR since FY21 as the commercial foundation underpinning investor demand.
Key upcoming milestones include:
- April 2026: $8 million institutional placement completed
- 31 May 2026: $0.26 Options expiry resulted in $6.56 million total proceeds secured
- 2026 AGM: Shareholder vote required for approval of Piggyback Options under Shortfall Agreement
- 31 May 2028: Piggyback Options expiry ($0.38 strike price)
The staged option structure creates visibility on potential future funding events whilst current proceeds support near-term contract execution. If the Piggyback Options are exercised in full before 31 May 2028, BluGlass would receive an additional capital injection at the $0.38 strike price, further strengthening its financial position without immediate dilution.
BluGlass’s recapitalisation efforts reflect Board prioritisation of maintaining sufficient working capital to deliver on existing contracts, invest in manufacturing capability, and convert new opportunities from its customer pipeline. The company’s position as one of few end-to-end GaN laser manufacturers globally, combined with recent technical achievements, underpins the strategic rationale for this funding structure.
Don’t Miss the Next Tech Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements hit the ASX across Tech, Healthcare, Finance, and more.